- Cell Design Labs (“CDL”) acquisition enabled Gilead with CAR-T enhancing technologies (synNotch and Throttle).
- The Alpine partnership enabled Gilead to access TIP-vIgD in ensuring that CAR-T works while the CDL acquisition added further insurance to Gilead’s CAR-T.
- This is an abbreviated version of the in-depth Integrated BioSci Research available exclusively to subscribers of Integrated BioSci Investing marketplace.
Trading Analytics And Recent News
After going ex-dividend on Dec. 14, 2017, the share price of Gilead Sciences (NASDAQ:GILD) took a temporarily dip, then bounced back above $75.57. Moreover, the stock is showing signs of rebounding once it receded significantly following the robust rise from the Kite Pharma (NASDAQ:KITE) acquisition back on Aug. 28. Specifically, the share traded up by $3.16 for 4.36% gains for the past month. What investors should be asking is whether the trading momentum will continue its trajectory going forward.
We’ve covered key grounds in this stellar grower that is hitting the next growth spurts with various organic and acquisition programs. In specific, we’ve detailed our initial coverage of the Chimeric Antigen Receptor and T-Cell Receptor (“CAR-T”) platform, the Hepatitis C franchise expansion into the vast China market, as well as the nonalcoholic steatohepatitis (“NASH”). In this report, we’ll go over the recent acquisition of a CAR-T enhancing technology provider, CDL (and how it fits into the overall growth structure of this stellar firm).